BioCentury
ARTICLE | Clinical News

BDM-E: Phase I/II data

July 24, 2006 7:00 AM UTC

Data from 15 evaluable patients in a double-blind, placebo-controlled Phase I/II study showed that subcutaneous BDM-E did not cause any adverse effects. BDM-E was administered for 10 days with follow-...